Supersaturated Oxygen (SSO2) Therapy in STEMI Treatments

Published: 06 December 2021

Views:
7614
Likes:
7

Views:
7614
Likes:
7
Share:

Now Playing
Part 3 | Session 1 of 3
Introduction
Nadia Sutton

Up Next
Part 3 | Session 2 Overview of the Problem: Microvascular Obstruction and Infarct Size in STEMI
Suzanne de Waha
Part 3 | Session 3 Questions and Answers
Nadia Sutton, Suzanne de Waha, Dan Burkhoff, Babar Basir, Jay Traverse

Part 1 | Session 1 Why is Infarct Size Reduction Important Gregg Stone, Robert Kloner

Part 1 | Session 2 Impact of Microvascular Obstruction Robert Kloner, Gregg Stone

Part 1 | Session 3 What is SSO2 Therapy Gregg Stone, Robert Kloner

Part 1 | Session 4 Infarct Size and Clinical Outcomes Robert Kloner, Gregg Stone

Part 1 | Session 5 SSO2 Therapy and Infarct Size Reduction Gregg Stone, Robert Kloner

Part 1 | Session 6 Questions and Answers Gregg Stone, Robert Kloner

Part 2 | Session 1 Current State of STEMI Care Dan Burkhoff, Steven Yakubov, Andreas Schäfer, Richard Schatz

Part 2 | Session 2 Evolution of STEMI Treatment Dan Burkhoff, Richard Schatz, Steven Yakubov, Andreas Schäfer

Part 2 | Session 3 SSO2 Mechanism of Action Richard Schatz, Dan Burkhoff, Steven Yakubov, Andreas Schäfer

Part 2 | Session 4 Clinical Results of SSO2 Therapy with Case Presentation Steven Yakubov, Dan Burkhoff, Andreas Schäfer, Richard Schatz

Part 2 | Session 5 Case Presentation by Dr A Schäfer Andreas Schäfer, Dan Burkhoff, Steven Yakubov, Richard Schatz

Part 2 | Session 6 Questions and Answers Dan Burkhoff, Richard Schatz, Steven Yakubov, Andreas Schäfer

Average (ratings)

No ratings

Your rating

Overview

Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature. TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce the infarct size in STEMI patients.

During this series of webinars on Supersaturated Oxygen (SSO2) Therapy, our faculty of renowned international experts will discuss and dissect the mechanisms and data around this promising new therapy for STEMI patients.

This broadcast series is supported by

Key Objectives

Understand how SSO2 Therapy works
Hear about trends in STEMI treatment
Explore the role of microvascular obstruction and infarct size in outcomes
Understand the science behind SSO2 Therapy

Target Audience

This series is designed for the entire cardiology community:

Interventional Cardiologists
Cardiologists
Clinical Fellows and Trainees

More from this programme

Part 1

Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment

Learn about the mechanism and data around SSO2 Therapy for STEMI patients with leading experts, Dr Gregg Stone and Dr Robert Kloner.

6 sessions
Why is Infarct Size Reduction Important	Watch now
Impact of Microvascular Obstruction	Watch now
What is SSO2 Therapy	Watch now
Infarct Size and Clinical Outcomes	Watch now
SSO2 Therapy and Infarct Size Reduction	Watch now
Questions and Answers	Watch now

Part 2

SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation with Global Thought Leaders

Learn about this promising new therapy for STEMI patients and hear from global thought leaders, Dr Dan Burkhoff, Dr Steven Yakubov, Dr Andreas Schäfer and Dr Richard Schatz, about their experiences with it.

6 sessions
Current State of STEMI Care	Watch now
Evolution of STEMI Treatment	Watch now
SSO2 Mechanism of Action	Watch now
Clinical Results of SSO2 Therapy with Case Presentation	Watch now
Case Presentation by Dr A Schäfer	Watch now
Questions and Answers	Watch now

Part 3

Infarct Size, Microvascular Obstruction and Outcomes in STEMI: An Expert Panel Discussion

Learn about which patients are at greatest risk of microvascular obstruction (MVO) and large infarcts, how we can diagnose MVO and how we can treat MVO and infarct. Moderated by Dr Nadia Sutton, hear global thought leaders Dr Babar Basir, Dr Dan Burkhoff, Dr Suzanne de Waha and Dr Jay Traverse answer these questions.

3 sessions
Introduction	Watch now
Overview of the Problem: Microvascular Obstruction and Infarct Size in STEMI	Watch now
Questions and Answers	Watch now

Faculty Biographies

Nadia Sutton

Assistant Professor and Interventional Cardiologist

Dr Nadia Sutton is an Assistant Professor, interventional cardiologist and vascular biologist in the Division of Cardiovascular Medicine and the Frankel Cardiovascular Center at University of Michigan, Michigan, US.

View full profile